Fortra Drug Interactions

Potent inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and HIV protease inhibitors) are likely to markedly increase plasma levels of Budesonide and concomitant use should be avoided. If this is not possible the time interval between administration of the inhibitor and Budesonide should be as long as possible.
β blockers (including eye drops) may not only block the pulmonary effect of β agonists, such as Formoterol but may produce severe bronchospasm in patients with asthma.
Therefore, patients with asthma should not normally be treated with β blockers. However, under certain circumstances, there may be no acceptable alternatives to the use of β adrenergic blocking agents in patients with asthma. In this setting, cardioselective β blockers could be considered, although they should be administered with caution.
Concomitant treatment with quinidine, disopyramide, procainamide, phenothiazines and tricyclic antidepressants can prolong the QTc-interval and increase the risk of ventricular arrhythmias.
L-Dopa, L-thyroxine, oxytocin and alcohol can impair cardiac tolerance towards β₂-sympathomimetics.
Budesonide + Formoterol inhaler should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within two weeks of discontinuation of such agents, because the action of Formoterol on the vascular system may be potentiated by these agents.
There is an elevated risk of arrhythmias in patients receiving concomitant anesthesia with halogenated hydrocarbons.
Concomitant use of other β adrenergic drugs or anticholinergic drugs can have a potentially additive bronchodilating effect.
Hypokalemia may increase the disposition towards arrhythmias in patients who are treated with digitalis glycosides.
The ECG changes and/or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by β agonists, especially when the recommended dose of the β agonist is exceeded. Caution is advised in the coadministration of Budesonide + Formoterol inhaler with non-potassium sparing diuretics.